CRBU Caribou Biosciences, Inc. Stock Quote

CRBU [NASD]

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	0.90%	Shs Outstand	60.55M	Perf Week	2.90%
Market Cap	346.59M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	1.36%	Shs Float	52.62M	Perf Month	-30.90%
Income	-72.90M	PEG	-	EPS next Q	-0.36	Inst Own	57.00%	Short Float	6.38%	Perf Quarter	-39.19%
Sales	10.70M	P/S	32.39	EPS this Y	-249.40%	Inst Trans	9.82%	Short Ratio	4.17	Perf Half Y	-63.61%
Book/sh	6.14	P/B	0.93	EPS next Y	-18.30%	ROA	-19.30%	Target Price	29.43	Perf Year	-
Cash/sh	5.80	P/C	0.98	EPS next 5Y	2.30%	ROE	-26.10%	52W Range	4.89 - 32.65	Perf YTD	-62.36%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-16.90%	52W High	-82.60%	Beta	-
Dividend %	-	Quick Ratio	13.80	Sales past 5Y	-	Gross Margin	-	52W Low	16.16%	ATR	0.65
Employees	97	Current Ratio	13.80	Sales Q/Q	68.80%	Oper. Margin	-	RSI (14)	36.78	Volatility	7.94% 10.07%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-35.90%	Profit Margin	-	Rel Volume	0.75	Prev Close	5.81
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 AMC	Payout	-	Avg Volume	806.08K	Price	5.68
Recom	1.40	SMA20	-18.58%	SMA50	-25.28%	SMA200	-58.53%	Volume	607,714	Change	-2.24%

Feb-18-22

Initiated

RBC Capital Mkts

Outperform

$22

Dec-01-21

Initiated

Oppenheimer

Outperform

$36

Nov-30-21

Initiated

H.C. Wainwright

Buy

$28

Nov-15-21

Upgrade

Citigroup

Neutral → Buy

$27

Aug-17-21

Initiated

SVB Leerink

Outperform

$32

Aug-17-21

Initiated

Citigroup

Neutral

$27

Aug-17-21

Initiated

BofA Securities

Buy

$30

Jun-13-22 02:41PM	Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability Benzinga -26.51%
02:06PM	This CRISPR Stock Plunged On Cell Therapy's Looming Question TheStreet.com
Jun-10-22 03:00AM	Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress GlobeNewswire -20.41%
Jun-01-22 04:05PM	Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022 GlobeNewswire
May-16-22 04:05PM	Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribous chRDNA Genome-Editing Technology in Primary Human T cells GlobeNewswire +8.58%
May-12-22 11:46AM	Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study Benzinga +22.17%
10:00AM	Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy GlobeNewswire
06:16AM	Here's What Analysts Are Forecasting For Caribou Biosciences, Inc. (NASDAQ:CRBU) After Its First-Quarter Results Simply Wall St.
May-11-22 04:00PM	Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors GlobeNewswire -9.05%
May-03-22 04:05PM	Caribou Biosciences to Present at Upcoming Investor Conference GlobeNewswire
May-02-22 04:30PM	Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) GlobeNewswire +7.16%
Apr-25-22 04:05PM	Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress GlobeNewswire
Apr-21-22 09:33AM	Here's Why We're Not Too Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation Simply Wall St.
09:09AM	9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller Insider Monkey
Apr-08-22 01:07PM	Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-25-22 12:55PM	How to future-proof your stock investments and outperform the market at the same time MarketWatch
Mar-21-22 04:02PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire -6.35%
Mar-08-22 08:19PM	Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-07-22 04:11PM	Caribou Biosciences to Present at Upcoming Investor Conferences GlobeNewswire
Mar-04-22 09:00AM	Women Who Lead: The CRISPR connections American City Business Journals
Mar-01-22 05:44PM	CRISPR ruling fallout is potentially big for UC, less so for Bay Area companies American City Business Journals -6.31%
Feb-28-22 08:15PM	University of California loses breakthrough CRISPR patent in PTO ruling American City Business Journals
Feb-22-22 09:17AM	10 Biotech Stocks to Sell Now According to Cathie Wood Insider Monkey
Feb-07-22 04:05PM	Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference GlobeNewswire
Jan-21-22 05:37AM	Is Caribou Biosciences, Inc. (NASDAQ:CRBU) Popular Amongst Insiders? Simply Wall St.
Jan-18-22 08:00AM	Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer GlobeNewswire -6.37%
Jan-04-22 04:05PM	Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.42%
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc GuruFocus.com
Dec-11-21 10:06PM	Hedge Funds Are Crazy About Caribou Biosciences Inc. (CRBU) Insider Monkey
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... GuruFocus.com
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... GuruFocus.com
Nov-17-21 04:05PM	Caribou Biosciences to Present at Upcoming Investor Conferences GlobeNewswire
Nov-09-21 04:05PM	Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-08-21 09:00AM	Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer GlobeNewswire
Oct-23-21 08:41AM	Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth Simply Wall St.
Oct-22-21 07:50AM	2 Penny Stocks Insiders Are Buying Benzinga
Oct-20-21 04:00PM	Caribou Biosciences to Present at Upcoming Investor Conferences GlobeNewswire
Oct-14-21 11:25AM	Caribou Biosciences Insider Trades $220K In Company Stock Benzinga +8.71%
Sep-29-21 04:05PM	Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors GlobeNewswire
Sep-27-21 04:05PM	Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-02-21 04:05PM	Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results GlobeNewswire +5.60%
04:05PM	Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology GlobeNewswire
Sep-01-21 08:00AM	Caribou Biosciences to Participate in Citis 16Th Annual BioPharma Virtual Conference GlobeNewswire
Aug-25-21 04:00PM	Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors GlobeNewswire
Jul-27-21 04:05PM	Caribou Biosciences Announces Closing of Upsized Initial Public Offering Business Wire
12:45PM	3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio Motley Fool
Jul-22-21 09:09PM	Caribou Biosciences Announces Pricing of Upsized Initial Public Offering Business Wire

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kanner Steven	Chief Scientific Officer	May 13	Option Exercise	1.88	74,420	140,081	302,059	May 17 08:51 PM
Haurwitz Rachel E.	President and CEO	May 09	Option Exercise	2.96	10,000	29,600	20,000	May 10 07:32 PM
Fischesser Ryan	VP of Finance and Controller	May 05	Option Exercise	3.40	2,274	7,733	115,518	May 06 07:28 PM
Fischesser Ryan	VP of Finance and Controller	Mar 15	Option Exercise	3.40	2,274	7,733	113,244	Mar 17 07:14 PM
Kanner Steven	Chief Scientific Officer	Mar 04	Option Exercise	2.90	10,720	31,036	227,639	Mar 07 07:58 PM
O'Byrne Jason	Chief Financial Officer	Feb 08	Option Exercise	4.11	24,336	100,021	24,336	Feb 08 07:27 PM
Haurwitz Rachel E.	President and CEO	Jan 26	Option Exercise	2.96	10,000	29,600	3,359,395	Jan 27 04:41 PM
Fischesser Ryan	VP of Finance and Controller	Jan 11	Buy	4.00	7,387	29,553	109,082	Jan 12 04:35 PM
Fischesser Ryan	VP of Finance and Controller	Dec 20	Buy	2.69	1,136	3,056	101,695	Dec 21 05:23 PM
MCCLUNG BARBARA G	Chief Legal Officer	Dec 07	Buy	2.69	6,127	16,482	348,971	Dec 08 06:06 PM
MCCLUNG BARBARA G	Chief Legal Officer	Oct 20	Buy	2.69	9,219	24,799	342,844	Oct 21 06:12 PM
Kanner Steven	Chief Scientific Officer	Oct 12	Buy	1.92	114,860	220,757	215,031	Oct 13 07:31 PM
Fischesser Ryan	VP of Finance and Controller	Oct 11	Buy	2.69	1,746	4,697	100,559	Oct 12 07:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience